Natural killer (NK) cells are cellular components of the innate immune system that play critical roles in protection against cancer and display potent antileukemia and antirejection activities. New therapeutic protocols aiming at improving the treatment of leukemias and cancers may commonly comprise the use of NK cells and thus require the availability of sufficient amounts of such cells. 1, 2 Common methods for NK-cell collection and expansion require serial leukapheresis that allow collection of mature NK cells from blood followed by long-term growth factor stimulation or can include classical ex vivo long-term expansion of human CD34 þ progenitor cells followed by NK-cell differentiation of the expanded cells. 3, 4 Here, we report a method for efficient ex vivo expansion of human NK progenitors, exclusive of the addition of exogenous cytokines or retrovirus gene transfer and based on supply of the HOXB4 transcription factor. In a previous work, our group had designed a protocol that allowed direct delivery of this homeoprotein into human hematopoietic stem cells (HSCs). 5 This model led to ex vivo expansion of human HSCs and myeloid progenitors with further maintenance of in vivo lympho-myeloid differentiation potential of HSCs. 5 However, NK progenitor expansion was not established. Thus, using a similar strategy, we demonstrate that HOXB4 protein transfer into CD34 þ CD38 lo/À immature human hematopoietic cells generates high number of NK progenitors able to develop functional mature NK cells.
Pools of 3 to 5 human umbilical cord blood cells (UCBs) were collected and immature CD34 þ CD38 lo/À cells were purified then co-cultured with the following murine stromal cell lines: MS-5, MS-5/SP-HOXB4 that actively secrete the HOXB4 protein or MS-5/EGFP as control. 5 From five independent experiments, after 3-week co-culture of CD34 þ CD38 lo/À cells with MS-5/SP-HOXB4, there were a 18-fold mean increase in CD34 þ cell numbers and a 30.5-fold mean increase in total cells (including 27.7% CD34 þ and 72.3% more mature CD34 À cells), whereas cells co-cultured with MS-5/EGFP were expanded by only 6.4-and 10.6-fold, respectively (including 25% CD34 þ and 75% more mature CD34 À cells). Thus, the relative expansion rates of CD34 þ cells and total cells co-cultured with MS5/SP-HOXB4, were respectively 3.471.1 and 370.6, when compared to control co-culture with MS-5/EGFP (Figure 1a , steps I and II and Figure 1b) . CD34 þ cells derived from these primary co-cultures were then purified and induced to differentiate into NK cells in secondary 3-week co-cultures with unmodified MS-5 cells and in presence of human AB serum, fetal calf serum and specific cytokines (Stem Cell Factor, Interleukin (IL)-2 and IL-15) (Figure 1a , steps II and III). In three independent experiments, NK-cell differentiation was examined on the basis of both the expression of CD56 cell surface antigen and the lack of CD3 T-cell marker. It must be emphasized that, whatever the type of MS-5 cell used (that is, MS-5/SP-HOXB4 or MS-5/EGFP), there were no significant differences in NK-cell differentiation potential of CD34 þ cells derived from primary co-cultures since percentages of NK cells were 49.4714.7% and 38.2710.4% when produced from MS-5/SP-HOXB4 and MS-5/EGFP co-cultures, respectively (P ¼ 0.3) (Figure 1c Figure 1b ) and secondary NK cultures (Figure 1d ) led to dramatic overall enrichment in total NK cells from CD34 þ CD38 lo/À cells, as presented in Table 1 . The important variability of NK-cell progenitor expansion from one experiment to another is most probably related to variability in the number, quality and in vitro growth potential of stem cells present in the various cord blood samples. However, the relative expansion rate of total NK cells obtained from CD34 þ CD38 lo/À cells cultured in presence of HOXB4, when compared to the number of NK cells from CD34 þ CD38 lo/À cells cultured without HOXB4, was reproducible and reached 13.871.6 as a mean (Table 1 and Figure 1e ). Altogether, these results demonstrate that delivery of HOXB4 dramatically improves the expansion of NK progenitor cells while not modifying their differentiation potential as compared to control cultures.
We next examined NK cells derived from CD34 þ CD38
lo/À cells exposed to HOXB4 to ascertain whether they exhibited normal phenotype and function. Part of CD3 À CD56 þ cells expressed CD16, overall phenotypic characteristics of mature NK cells. Moreover, they expressed the natural cytotoxicity receptors: NKp46, NKp30 and NKp44, as well as the activating NKG2D receptor (Figure 2a ). In addition, the dimeric inhibitory NK receptor CD94/NKG2A was present on differentiated NK cells as well as the inhibitory receptors p58.1, p58.2 and p70 ( Figure 2a ). These results ascertain that NK cells derived from CD34 þ CD38 lo/À co-cultured with MS-5/SP-HOXB4 display normal NK-cell phenotype. The cytolytic activity of these cells was tested against K562 target cells ( Figure 2b) . 7 NK cells derived from co-cultures in presence of HOXB4 exerted a lytic activity (around 40%) comparable to that reported for NK cells derived from UCB CD34 þ cells cultured in similar conditions, 7 or for activated primary NK cells isolated from UCB. 8 Taken together, our results show that transfer of the HOXB4 protein into CD34 þ CD38 lo/À immature cells 5 efficiently promotes NK progenitor cell expansion as compared to day-0 nonexpanded CD34 þ CD38 lo/À cells and to control co-cultures.
Moreover, this ex vivo expansion of progenitor cells should be considered as a powerful strategy as compared to NK-cell progenitor expansion performed from classical long-term culture of hematopoietic progenitors. 4 Such expansion mediated by HOXB4 does not impair the functionality of resulting NK cells since, when generated from progenitors expanded by HOXB4, they can be further activated to fully differentiated NK cells that display cytotoxic activity against leukemic cells. The use of purified recombinant HOXB4 protein will be required in the perspective of NK-cell adoptive immunotherapy of malignancies. Indeed, activated NK cells represent potential therapy in hematopoietic malignant dis- Letters to the Editor orders, during or after allogenic bone marrow transplantation. NK cells are now recognized as important cytotoxic effectors involved in the graft-versus-leukemia (GvL) and in the maintenance of remission in a minimal residual disease setting after autologous transplantation. The expansion model we developed could also provide a promising additional tool for immunotherapy prospects particularly in patients with NK progenitor cell deficiencies.
Acknowledgements
This work was supported by grants from the Agence Nationale pour la Recherche (ANR) and the Ligue Nationale contre le Cancer (LNCC). We thank Françoise Pflumio, Sylvie Gisselbrecht and Béla Papp for helpful discussions, Micaël Yagello for flow cytometry cell sorting, Azzedine Yacia and Sylvie Da Rocha for technical assistance. ETV6-PDGFRB results from the t(5;12)(q31-33;p13) and, although rare, is the most frequent of at least 15 known PDGFRB fusion genes. ETV6-PDGFRB is usually seen in patients with chronic myelomonocytic leukaemia, atypical chronic myeloid leukaemia (aCML) or chronic eosinophilic leukaemia (CEL), with most patients exhibiting peripheral blood or bone marrow eosinophilia. Although ETV6-PDGFRB disease may be controlled with conventional therapy (hydroxyurea, busulphan, interferon-a), many die from transformed disease or other causes. More recently, however, imatinib has emerged as the standard therapy for PDGFR-rearranged patients, with most experiencing sustained haematologic and cytogenetic remission, and many achieving molecular remission.
1 Molecular confirmation of a PDGFR rearrangement is therefore important for appropriate clinical management and monitoring response to therapy. For the t(5;12)(q31-33;p13), confirmation of the presence of ETV6-PDGFRB is particularly important since many cases with this translocation have a distinct molecular aetiology, with upregulation of IL-3 expression and no involvement of PDGFRB.
2
In the great majority of positive cases, ETV6 exon 4 splices to PDGFRB exon 11 and is typically detected by reverse transcription PCR (RT-PCR) using primers directed to ETV6 exon 3 or 4 and PDGFRB exon 11. Out of 10 positive cases we have detected with these primer combinations, only one had a variant fusion in which ETV6 exon 4 was fused to PDGFRB exon 9 (unpublished data). Recently, a patient with idiopathic myelofibrosis and an ETV6 exon 7-PDGFRB exon 10 fusion was reported and it was suggested that this novel transcript may have accounted for the somewhat unusual clinical phenotype seen in this case. 3 Importantly, both these variants are detectable using the standard primer sets above. Here we report a novel ETV6-PDGFRB fusion with breakpoints outside this region.
A 19-year-old male (E1026) presented to the outpatient department with a 2-month history of fever. On examination he was found to have generalized lymphadenopathy, hepatosplenomegaly and bony swellings over the left clavicle and right tibia. There were no bleeding manifestations. A peripheral blood smear showed a total leucocyte count exceeding 100 Â 10 9 /l with a left shift. The bone marrow aspirate was suggestive of a myeloproliferative disorder with an increase in the number of basophils and eosinophils. Fine needle aspiration of the lymph node showed infiltration by blasts which cytochemistry revealed to be negative for myeloperoxidase and periodic acid schiff. Flow cytometry of the peripheral blood and lymph node aspirate was positive for myeloid markers (CD 11c, 13, 15 and 33) along with CD45 and myeloperoxidase. BCR-ABL was not detected by RT-PCR and cytogenetics showed a t(5;12)(q31-33;p13). A diagnosis of atypical CML in blast crisis was made. Despite the fact that ETV6-PDGFRB was not detected by RT-PCR, he was started on imatinib mesylate (300 mg twice a day) after taking informed consent. The patient had a complete haematological and cytogenetic response (including complete regression of the lymph nodes, bony swellings and hepatosplenomegaly) at 3 months post-treatment. He continues in remission on 600 mg/ day imatinib, 1 year after diagnosis.
In view of the excellent response to imatinib, we performed further analysis to determine if PDGFRB was involved (material was not available for molecular cytogenetic analysis). We have previously reported a simple multiplex RT-PCR assay to identify PDGFRA fusions by looking for overexpression of sequence encoding the kinase domain (which is retained in any fusion) relative to that encoding the extracellular domain (which is expressed only by the normal, unrearranged gene). 4 Attempts to establish a similar assay for PDGFRB were only partially successful and therefore we developed an analogous strategy using multiplex ligation-dependent probe amplification (MLPA). We designed probes targeting the region encoding the kinase domain and upstream sequences of PDGFRA, PDGFRB and FGFR1. MLPA was performed on patient and control cDNA essentially as described. 5 The cDNA MLPA assay detected relative overexpression of the PDGFRB kinase domain in 9 of 9 patients known to harbour PDGFRB fusion genes but not in 16 normal controls. Overexpression of the kinase domain was also seen for E1026, suggesting the presence of a PDGFRB fusion (Figure 1a) .
